Advertisement
UK markets closed

  • NIKKEI 225

    38,274.05
    -131.61 (-0.34%)
     

  • HANG SENG

    17,763.03
    +16.12 (+0.09%)
     

  • CRUDE OIL

    79.14
    +0.14 (+0.18%)
     

  • GOLD FUTURES

    2,329.60
    +18.60 (+0.80%)
     

  • DOW

    37,903.29
    +87.37 (+0.23%)
     

  • Bitcoin GBP

    46,316.81
    -1,734.73 (-3.61%)
     

  • CMC Crypto 200

    1,202.07
    -136.99 (-10.23%)
     

  • NASDAQ Composite

    15,605.48
    -52.34 (-0.33%)
     

  • UK FTSE All Share

    4,418.60
    -11.65 (-0.26%)
     
Money:

Family finances

Who is the breadwinner in your family and does it matter?

OKYO Pharma Limited ("OKYO" or the "Company") - Result of Annual General Meeting

OKYO Pharma LTD
·1-min read

LONDON, Sept. 27, 2021 (GLOBE NEWSWIRE) -- OKYO (LSE: OKYO), the life sciences and biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain, is pleased to announce that at the Annual General Meeting, which was held at 10:00 a.m. today, all resolutions were duly passed.

The results of the proxy voting will be available shortly on the Company's website, https://www.okyopharma.com/news.

About OKYO Pharma Limited

OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF) is a life sciences and biotechnology company admitted to listing on the standard segment of the Official List of the UK Financial Conduct Authority and to trading on the main market for listed securities of London Stock Exchange plc. OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain.

Enquiries:

OKYO Pharma Limited Willy Simon +44 (0)20 7495 2379

For further information, please visit the Company's website at www.okyopharma.com.